---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-22-000007"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2022-02-23T23:59:59+00:00"
generated_at: "2026-06-27T05:48:29.790972+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Integra Q4 revenue $405.5M (+8.3% organic); adj EPS $0.84 flat; guides FY2022 adj EPS $3.27-3.35

## Summary
- Q4 reported revenue $405.5M (+4.3% reported, +8.3% organic); GAAP EPS $0.53 vs $1.09 (prior-year $59.2M tax benefit); adjusted EPS $0.84 flat.
- Full-year 2021 revenue $1,542.4M (+12.4% reported, +14.2% organic); GAAP EPS $1.98 vs $1.57; adjusted EPS $3.18 vs $2.45.
- Q4 Codman Specialty Surgical organic growth +9.0%; Tissue Technologies organic +6.7%.
- FY2022 guidance: revenue $1,580-1,600M (organic +3.5-5%); adjusted EPS $3.27-3.35; Q1 revenue $357-365M, adj EPS $0.67-0.71.
- Entered $125M accelerated share repurchase on Jan 12, 2022, expected to complete in H1 2022.

## SEC filing metadata
- accession: 0000917520-22-000007
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2022-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752022000007/0000917520-22-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752022000007/iart-20220223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-22-000007
- JSON: https://secwatch.observer/filing/0000917520-22-000007.json
- Plain text: https://secwatch.observer/filing/0000917520-22-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.